Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in The Netherlands

SA van Laar, KB Gombert-Handoko… - Frontiers in …, 2022 - frontiersin.org
The number of treatment options for patients with metastatic renal cell carcinoma (mRCC)
has significantly grown in the last 15 years. Although randomized controlled trials are …

Conception et validation de modèles optimaux pour le ciblage thérapeutique en oncologie par des méthodes issues de l'intelligence artificielle

V Leclerc - 2022 - theses.hal.science
La prise en charge des cancers est aujourd'hui une priorité de santé publique. Pour cela se
développent de plus en plus de nouveaux traitements dits de précision, et ce que l'on …

Themes in Clinical Pharmacology and Therapeutics.

PH van der Graaf, AB Gerding - Clinical Pharmacology & …, 2021 - search.ebscohost.com
If, for instance, you are a researcher in the United Kingdom or Germany, you may be eligible
to have OA fees covered through country-level transitional agreements Wiley has agreed to …

[PDF][PDF] an, Gombert-Handoko, KB, Groenwold, RHH, Hulle, T. an der, Visser, L

S Laar - E., Houtsma, D.,… Zwa eling, 2022 - scholarlypublications …
The number of treatment options for patients with metastatic renal cell carcinoma (mRCC)
has significantly grown in the last 15 years. Although randomized controlled trials are …

[PDF][PDF] an.(2023, October 12)

S Laar - from https://hdl. handle. net/1887/3643700 … - scholarlypublications …
Abstract Introduction: Nivolumab (N), pembrolizumab (P), and dabrafenib plus trametinib
(D+ T) are registered as adjuvant treatments for resected stage III and IV melanoma since …

[引用][C] Clinical Pharmacology and Therapeutics: 2020 in Review

PH van der Graaf - Clinical Pharmacology & Therapeutics, 2020 - Wiley Online Library
Pharmacology & Therapeutics (CPT) leadership baton to a new editorial team. To mark the
occasion, a themed issue “Clinical Pharmacology & Therapeutics 2030” was published at …